The Experts below are selected from a list of 756 Experts worldwide ranked by ideXlab platform
Heike E. Daldrup-link - One of the best experts on this subject based on the ideXlab platform.
-
Ferumoxytol Can Be Used for Quantitative Magnetic Particle Imaging of Transplanted Stem Cells
Molecular Imaging and Biology, 2019Co-Authors: Hossein Nejadnik, Prachi Pandit, Olga Lenkov, Arian Pourmehdi Lahiji, Ketan Yerneni, Heike E. Daldrup-linkAbstract:Purpose To evaluate, if clinically translatable ferumoxytol nanoparticles can be used for in vivo detection and quantification of stem cell transplants with magnetic particle imaging (MPI). Procedures Mesenchymal stem cells (MSCs) were labeled with ferumoxytol or Ferucarbotran and underwent MPI, magnetic resonance imaging (MRI), Prussian blue staining, and inductively coupled plasma (ICP) spectrometry. Unlabeled, ferumoxytol, and Ferucarbotran-labeled MSCs were implanted in calvarial defects of eight mice and underwent MPI, MRI, and histopathology. The iron concentration calculated according to the MPI signal intensity and T2 relaxation times of the three different groups were compared using an analysis of variance (ANOVA) with Bonferroni correction, and a p
-
Ferumoxytol Can Be Used for Quantitative Magnetic Particle Imaging of Transplanted Stem Cells
Molecular Imaging and Biology, 2018Co-Authors: Hossein Nejadnik, Prachi Pandit, Olga Lenkov, Arian Pourmehdi Lahiji, Ketan Yerneni, Heike E. Daldrup-linkAbstract:To evaluate, if clinically translatable ferumoxytol nanoparticles can be used for in vivo detection and quantification of stem cell transplants with magnetic particle imaging (MPI). Mesenchymal stem cells (MSCs) were labeled with ferumoxytol or Ferucarbotran and underwent MPI, magnetic resonance imaging (MRI), Prussian blue staining, and inductively coupled plasma (ICP) spectrometry. Unlabeled, ferumoxytol, and Ferucarbotran-labeled MSCs were implanted in calvarial defects of eight mice and underwent MPI, MRI, and histopathology. The iron concentration calculated according to the MPI signal intensity and T2 relaxation times of the three different groups were compared using an analysis of variance (ANOVA) with Bonferroni correction, and a p
-
BRIEF ARTICLE Labeling Human Mesenchymal Stem Cells with Fluorescent Contrast Agents: the Biological Impact
2016Co-Authors: Sophie E. Boddington, Elizabeth J. Sutton, Tobias D. Henning, Er J. Nedopil, Barbara Sennino, Anne Kim, Heike E. Daldrup-linkAbstract:Purpose: This study aims to determine the effect of human mesenchymal stem cell (hMSC) labeling with the fluorescent dye DiD and the iron oxide nanoparticle Ferucarbotran on chondrogenesis. Procedures: hMSCs were labeled with DiD alone or with DiD and Ferucarbotran (DiD/ Ferucarbotran). hMSCs underwent confocal microscopy, optical imaging (OI), and magnetic resonance (MR) imaging. Chondrogenesis was induced by transforming growth factor-b and confirmed by histopathology and glycosaminoglycan (GAG) production. Data of labeled and unlabeled hMSCs were compared with a t test. Results: Cellular uptake of DiD and Ferucarbotran was confirmed with confocal microscopy. DiD labeling caused a significant fluorescence on OI, and Ferucarbotran labeling caused a significant T2 * effect on MR images. Compared to nonlabeled controls, progenies of labeled MSCs exhibited similar chondrocyte morphology after chondrogenic differentiation, but the labeled cells demonstrated significantly reduced GAG production (pG0.05). Conclusion: DiD and DiD/Ferucarbotran labeling of hMSC does not interfere with cell viability or morphologic differentiation into chondrocytes, but labeled cells exhibit significantly less GAG production compared to unlabeled cells
-
Labeling Human Mesenchymal Stem Cells with Fluorescent Contrast Agents: the Biological Impact
Molecular Imaging and Biology, 2011Co-Authors: Sophie E. Boddington, Elizabeth J. Sutton, Tobias D. Henning, Barbara Sennino, Alexander J. Nedopil, Heike E. Daldrup-linkAbstract:Purpose This study aims to determine the effect of human mesenchymal stem cell (hMSC) labeling with the fluorescent dye DiD and the iron oxide nanoparticle Ferucarbotran on chondrogenesis. Procedures hMSCs were labeled with DiD alone or with DiD and Ferucarbotran (DiD/Ferucarbotran). hMSCs underwent confocal microscopy, optical imaging (OI), and magnetic resonance (MR) imaging. Chondrogenesis was induced by transforming growth factor-b and confirmed by histopathology and glycosaminoglycan (GAG) production. Data of labeled and unlabeled hMSCs were compared with a t test. Results Cellular uptake of DiD and Ferucarbotran was confirmed with confocal microscopy. DiD labeling caused a significant fluorescence on OI, and Ferucarbotran labeling caused a significant T2* effect on MR images. Compared to nonlabeled controls, progenies of labeled MSCs exhibited similar chondrocyte morphology after chondrogenic differentiation, but the labeled cells demonstrated significantly reduced GAG production ( p
-
Labeling Human Mesenchymal Stem Cells with Fluorescent Contrast Agents: the Biological Impact
Molecular imaging and biology, 2010Co-Authors: Sophie E. Boddington, Elizabeth J. Sutton, Tobias D. Henning, Barbara Sennino, Anne Kim, Alexander J. Nedopil, Heike E. Daldrup-linkAbstract:Purpose This study aims to determine the effect of human mesenchymal stem cell (hMSC) labeling with the fluorescent dye DiD and the iron oxide nanoparticle Ferucarbotran on chondrogenesis.
Hironobu Nakamura - One of the best experts on this subject based on the ideXlab platform.
-
Safety of Ferucarbotran in MR imaging of the liver: A pre- and postexamination questionnaire-based multicenter investigation
Journal of magnetic resonance imaging : JMRI, 2009Co-Authors: Hiromitsu Onishi, Yasuharu Imai, Tonsok Kim, Masatoshi Hori, Takamichi Murakami, Shinji Hirohashi, Mitsuru Matsuki, Yoshifumi Narumi, Kousuke Sakurai, Hironobu NakamuraAbstract:Purpose To prospectively investigate, by means of a pre-and postexamination questionnaire, the types and frequency of adverse reactions to Ferucarbotran (Resovist), a superparamagnetic iron oxide (SPIO) contrast agent. Materials and Methods This study was approved by the ethics committee of each of the institutions involved, and all patients gave written informed consent. One questionnaire asking about baseline symptoms before the injection of Ferucarbotran, and one about adverse events over a period of seven days after injection were given to 315 patients who underwent Ferucarbotran-enhanced magnetic resonance imaging (MRI) of the liver at several institutions. The data for baseline symptoms were used for reference to exclude false-positive adverse reactions and were also compared with the adverse event data to determine with McNemar's chi-squared test the incidence of each symptom. Results Before MR examination, 249 clinical symptoms were reported by 102 of 315 patients (32.4%). After the injection of Ferucarbotran, 169 adverse events were observed in 78 patients (24.8%). Eventually, 70 adverse events occurring in 45 patients (14.3%) were judged to be adverse reactions to Ferucarbotran, defined as possibly or definitely Ferucarbotran-related events. All reactions were of mild intensity. Conclusion Ferucarbotran can be considered safe for clinical use in liver MRI. J. Magn. Reson. Imaging 2009;29:106–111. © 2008 Wiley-Liss, Inc.
-
Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using Ferucarbotran-enhanced MR imaging
European journal of radiology, 2008Co-Authors: Hiroki Higashihara, Tonsok Kim, Hiromitsu Onishi, Masatoshi Hori, Takamichi Murakami, Saki Nakata, Keigo Osuga, Kaname Tomoda, Hironobu NakamuraAbstract:Abstract Purpose To evaluate ability of Ferucarbotran-enhanced MR imaging (MRI) in differentiating metastases from nonsolid benign lesions of the liver according to signal-intensity characteristics. Materials and methods Sixty-six consecutive patients, who had 138 focal hepatic lesions (26 cysts, 11 hemangiomas, and 101 metastases), underwent Ferucarbotran-enhanced MRI. The signal-intensity pattern of each kind of lesion relative to the liver parenchyma on Ferucarbotran-enhanced T2* and heavily T1-weighted gradient-echo images were assessed and categorized into the following three categories: high-intensity and iso-intensity, respectively (category A), high and low (category B), and iso- and low-intensity (category C). For category B, lesions were subdivided into two groups based on single-shot half-Fourier RARE images: category B1 (not significantly high-intensity) and category B2 (significantly high-intensity). Results Category A had 11 hemangiomas and 2 metastatic tumors, category B1 had 97 metastatic tumors, category B2 had 2 metastatic tumors and 9 cysts, and category C had 17 cysts. When a tumor with a signal intensity of category A was considered to be hemangioma, category B1 metastasis, and category B2 and C cyst, the diagnostic accuracy for differentiating these lesions was 97% (134/138). Conclusion The combination of signal-intensity pattern on Ferucarbotran-enhanced T2*- and heavily T1-weighted gradient-echo MRI has ability to differentiate liver metastases from nonsolid benign lesions. However, T2-weighted single-shot half-Fourier RARE imaging should also be employed to achieve better performance.
-
hemodynamic characterization of focal hepatic lesions role of Ferucarbotran enhanced dynamic mr imaging using t2 weighted multishot spin echo echo planar sequence
Journal of Magnetic Resonance Imaging, 2006Co-Authors: Masatoshi Hori, Tonsok Kim, Hiromitsu Onishi, Takamichi Murakami, Riccardo Iannaccone, Carlo Catalano, Kaname Tomoda, Hisashi Abe, R Passariello, Hironobu NakamuraAbstract:Purpose To investigate the role of Ferucarbotran-enhanced dynamic MR imaging using multishot spin-echo echo-planar sequence in the evaluation of hemodynamics of focal hepatic lesions. Materials and Methods Sixty-three focal hepatic lesions (24 benign and 39 malignant) from 53 consecutive patients who underwent both Ferucarbotran-enhanced MR imaging and dynamic computed tomography (CT) were included in this study. MR imaging was performed with a 1.5-T scanner with a phased-array coil. T2-weighted multishot spin-echo echo-planar sequences (TR/TE = 1714–2813/80 msec) were obtained during a single breathhold before and 15, 60, 120, 180, and 600 seconds after intravenous injection of Ferucarbotran. The enhancement patterns of lesions were classified into three categories by a study coordinator on the basis of dynamic CT images as hypervascular, hypovascular, and hemangioma type. The study coordinator created mean contrast-to-noise ratio of lesions vs. time curves for each enhancement pattern for quantitative analyses. Moreover, three radiologists separately and blindly reviewed MR images, and then assigned three confidence scores for the three enhancement patterns to each lesion. Sensitivity, specificity, and receiver operating characteristic analyses were performed. Results Quantitative analyses showed characteristic enhancement curves for each enhancement pattern. Mean sensitivities/specificities were 0.816/0.882, 0.897/0.863, and 0.800/0.989 for hypervascular, hypovascular, and hemangioma types, respectively. Mean areas under the receiver operating characteristic curve were 0.886 for hypervascular type and 0.913 for hypovascular type. Conclusion Ferucarbotran-enhanced dynamic MR imaging can be used to successfully characterize the hemodynamics of focal hepatic lesions. J. Magn. Reson. Imaging 2006. © 2006 Wiley-Liss, Inc.
-
Hemodynamic characterization of focal hepatic lesions: Role of Ferucarbotran‐enhanced dynamic MR imaging using T2‐weighted multishot spin‐echo echo‐planar sequence
Journal of magnetic resonance imaging : JMRI, 2006Co-Authors: Masatoshi Hori, Tonsok Kim, Hiromitsu Onishi, Takamichi Murakami, Riccardo Iannaccone, Carlo Catalano, Roberto Passariello, Kaname Tomoda, Hisashi Abe, Hironobu NakamuraAbstract:Purpose To investigate the role of Ferucarbotran-enhanced dynamic MR imaging using multishot spin-echo echo-planar sequence in the evaluation of hemodynamics of focal hepatic lesions. Materials and Methods Sixty-three focal hepatic lesions (24 benign and 39 malignant) from 53 consecutive patients who underwent both Ferucarbotran-enhanced MR imaging and dynamic computed tomography (CT) were included in this study. MR imaging was performed with a 1.5-T scanner with a phased-array coil. T2-weighted multishot spin-echo echo-planar sequences (TR/TE = 1714–2813/80 msec) were obtained during a single breathhold before and 15, 60, 120, 180, and 600 seconds after intravenous injection of Ferucarbotran. The enhancement patterns of lesions were classified into three categories by a study coordinator on the basis of dynamic CT images as hypervascular, hypovascular, and hemangioma type. The study coordinator created mean contrast-to-noise ratio of lesions vs. time curves for each enhancement pattern for quantitative analyses. Moreover, three radiologists separately and blindly reviewed MR images, and then assigned three confidence scores for the three enhancement patterns to each lesion. Sensitivity, specificity, and receiver operating characteristic analyses were performed. Results Quantitative analyses showed characteristic enhancement curves for each enhancement pattern. Mean sensitivities/specificities were 0.816/0.882, 0.897/0.863, and 0.800/0.989 for hypervascular, hypovascular, and hemangioma types, respectively. Mean areas under the receiver operating characteristic curve were 0.886 for hypervascular type and 0.913 for hypovascular type. Conclusion Ferucarbotran-enhanced dynamic MR imaging can be used to successfully characterize the hemodynamics of focal hepatic lesions. J. Magn. Reson. Imaging 2006. © 2006 Wiley-Liss, Inc.
Dong-ming Huang - One of the best experts on this subject based on the ideXlab platform.
-
Ferucarbotran a carboxydextran coated superparamagnetic iron oxide nanoparticle induces endosomal recycling contributing to cellular and exosomal egfr overexpression for cancer therapy
RSC Advances, 2015Co-Authors: Tsaihua Chung, Jong-kai Hsiao, Ming Yao, Szu-chun Hsu, Hon-man Liu, Dong-ming HuangAbstract:Superparamagnetic iron oxide (SPIO) nanoparticles have shown many impacts on stem cell attributes when they are used as labels for cellular magnetic resonance imaging (MRI) in the application of stem cell-based therapy. Although it is plausible that iron ions from the lysosomal degradation of SPIO nanoparticles are one of the possible candidates, the mechanisms underlying SPIO-induced cellular responses remain unclear. Herein, the mechanism of Ferucarbotran, an ionic SPIO, for the regulation of epidermal growth factor receptor (EGFR) expression in human mesenchymal stem cells (hMSCs) is explored. Ferucarbotran can be internalized into EGFR-localized endosomes, and the endosomal EGFRs in Ferucarbotran-labeled hMSCs, compared to unlabeled cells, are mainly localized on the early endosomes and recycling endosomes, but not on late endosomes/lysosomes, and thus escape from lysosomal degradation. Afterward, the recycling endosomal EGFRs are transferred to the cellular membrane and extracellular exosomal vesicles (exosomes) through back fusion and a secretory pathway, respectively, resulting in EGFR-overexpressed hMSCs and EGFR-overexpressed exosomes. Moreover, as EGFR-overexpressed hMSCs, EGFR-overexpressed exosomes can more effectively capture tumorous EGF than native exosomes, which may contribute to the inhibition of tumor growth. This is the first report to find that the SPIO nanoparticles have an impact on stem cell attributes through inducing endosomal recycling instead of them undergoing lysosomal degradation.
-
The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells.
Toxicology and applied pharmacology, 2010Co-Authors: Ying-chun Chen, Jong-kai Hsiao, Ming Yao, Szu-chun Hsu, Hon-man Liu, I-yin Lai, Yao-chang Chen, Chung-shi Yang, Dong-ming HuangAbstract:Abstract Superparamagnetic iron oxide (SPIO) nanoparticles are very useful for monitoring cell trafficking in vivo and distinguish whether cellular regeneration originated from an exogenous cell source, which is a key issue for developing successful stem cell therapies. However, the impact of SPIO labeling on stem cell behavior remains uncertain. Here, we show the inhibitory effect of Ferucarbotran, an ionic SPIO, on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. Ferucarbotran caused a dose-dependent inhibition of osteogenic differentiation, abolished the differentiation at high concentration, promoted cell migration, and activated the signaling molecules, β-catenin, a cancer/testis antigen, SSX, and matrix metalloproteinase 2 (MMP2). An iron chelator, desferrioxamine, suppressed all the above Ferucarbotran-induced actions, demonstrating an important role of free iron in the inhibition of osteogenic differentiation that is mediated by the promotion of cell mobilization, involving the activation of a specific signaling pathway.
-
The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles.
Biomaterials, 2009Co-Authors: Dong-ming Huang, Jong-kai Hsiao, Ying-chun Chen, Li-ying Chien, Ming Yao, Szu-chun Hsu, Lin-ai Tai, Hui-ying ChengAbstract:Superparamagnetic iron oxide (SPIO) nanoparticles are very useful in cell imaging; meanwhile, however, biosafety concerns associated with their use, especially on therapeutic stem cells, have arisen. Most studies of biosafety issues focus on whether the nanoparticles have deleterious effects. Here, we report that Ferucarbotran, an ionic SPIO, is not toxic to human mesenchymal stem cells (hMSCs) under the conditions of these experiments but instead increases cell growth. Ferucarbotran-promoted cell growth is due to its ability to diminish intracellular H2O2 through intrinsic peroxidase-like activity. Also, Ferucarbotran can accelerate cell cycle progression, which may be mediated by the free iron (Fe) released from lysosomal degradation and involves the alteration of Fe on the expression of the protein regulators of the cell cycle.
Jong-kai Hsiao - One of the best experts on this subject based on the ideXlab platform.
-
Ferucarbotran a carboxydextran coated superparamagnetic iron oxide nanoparticle induces endosomal recycling contributing to cellular and exosomal egfr overexpression for cancer therapy
RSC Advances, 2015Co-Authors: Tsaihua Chung, Jong-kai Hsiao, Ming Yao, Szu-chun Hsu, Hon-man Liu, Dong-ming HuangAbstract:Superparamagnetic iron oxide (SPIO) nanoparticles have shown many impacts on stem cell attributes when they are used as labels for cellular magnetic resonance imaging (MRI) in the application of stem cell-based therapy. Although it is plausible that iron ions from the lysosomal degradation of SPIO nanoparticles are one of the possible candidates, the mechanisms underlying SPIO-induced cellular responses remain unclear. Herein, the mechanism of Ferucarbotran, an ionic SPIO, for the regulation of epidermal growth factor receptor (EGFR) expression in human mesenchymal stem cells (hMSCs) is explored. Ferucarbotran can be internalized into EGFR-localized endosomes, and the endosomal EGFRs in Ferucarbotran-labeled hMSCs, compared to unlabeled cells, are mainly localized on the early endosomes and recycling endosomes, but not on late endosomes/lysosomes, and thus escape from lysosomal degradation. Afterward, the recycling endosomal EGFRs are transferred to the cellular membrane and extracellular exosomal vesicles (exosomes) through back fusion and a secretory pathway, respectively, resulting in EGFR-overexpressed hMSCs and EGFR-overexpressed exosomes. Moreover, as EGFR-overexpressed hMSCs, EGFR-overexpressed exosomes can more effectively capture tumorous EGF than native exosomes, which may contribute to the inhibition of tumor growth. This is the first report to find that the SPIO nanoparticles have an impact on stem cell attributes through inducing endosomal recycling instead of them undergoing lysosomal degradation.
-
Mechanism of Cellular Uptake and Impact of Ferucarbotran on Macrophage Physiology
PloS one, 2011Co-Authors: Chung-yi Yang, Jong-kai Hsiao, Jaw-lin Wang, Ming-fong Tai, Chih-peng Lin, Hon-man LiuAbstract:Superparamagnetic iron oxide (SPIO) nanoparticles are contrast agents used for magnetic resonance imaging. Ferucarbotran is a clinically approved SPIO-coated carboxydextran with a diameter of about 45–60 nm. We investigated the mechanism of cellular uptake of Ferucarbotran with a cell model using the murine macrophage cell line Raw 264.7. We observed a dose-dependent uptake of these SPIO particles by spectrophotometer analysis and also a dose-dependent increase in the granularity of the macrophages as determined by flow cytometry. There was a linear correlation between the side scattering mean value and iron content (P
-
mechanism of cellular uptake and impact of Ferucarbotran on macrophage physiology
PLOS ONE, 2011Co-Authors: Chung-yi Yang, Jong-kai Hsiao, Jaw-lin Wang, Ming-fong Tai, Chih-peng Lin, Hon-man LiuAbstract:Superparamagnetic iron oxide (SPIO) nanoparticles are contrast agents used for magnetic resonance imaging. Ferucarbotran is a clinically approved SPIO-coated carboxydextran with a diameter of about 45–60 nm. We investigated the mechanism of cellular uptake of Ferucarbotran with a cell model using the murine macrophage cell line Raw 264.7. We observed a dose-dependent uptake of these SPIO particles by spectrophotometer analysis and also a dose-dependent increase in the granularity of the macrophages as determined by flow cytometry. There was a linear correlation between the side scattering mean value and iron content (P<0.001, R2 = 0. 8048). For evaluation of the endocytotic pathway of these ingested SPIO particles, different inhibitors of the endocytotic pathways were employed. There was a significant decrease of side scattering counts in the cells and a less significant change in signal intensity based on magnetic resonance in the phenylarsine oxide-treated macrophages. After labeling with SPIO particles, the macrophages showed an increase in the production of reactive oxygen species at 2, 24, and 48 h; a decrease in mitochondrial membrane potential at 24 h; and an increase in cell proliferation at 24 h. We concluded that Ferucarbotran was internalized into macrophages via the clathrin-mediated pathway and can change the cellular behavior of these cells after labeling.
-
Direct Labeling of hMSC with SPIO: the Long-Term Influence on Toxicity, Chondrogenic Differentiation Capacity, and Intracellular Distribution
Molecular Imaging and Biology, 2011Co-Authors: Chung-yi Yang, Jong-kai Hsiao, Jaw-lin Wang, Hui-ying Cheng, Ming-fong Tai, Shin-tai Chen, Hon-man LiuAbstract:Purpose The purpose of this study was to evaluate the long-term cellular toxicity, labeling efficiency, chondrogenic differentiation capacity, and intracellular distribution following direct superparamagnetic iron oxide (SPIO) nanoparticle labeling of human mesenchymal stem cells (hMSCs) in the absence of transfection agents. Procedures hMSCs were incubated with a SPIO, Ferucarbotran, at concentrations of 0, 1, 10, and 100 μg Fe/ml for 24 or 72 h. The cell granularity and size change, reactive oxygen species generation, and mitochondria membrane potential were measured by flow cytometry. The differentiation capacity of the cells into chondrocytes was determined by Alcian blue and Safranin-O staining, immunocytochemical analysis, and reverse transcription polymerase chain reaction. Results The intracellular distribution of the internalized particles was visualized via confocal microscopy. No significant difference was found in the toxicity of labeled cells relative to controls. Successful chondrogenesis of Ferucarbotran-labeled hMSCs was confirmed. The intracellular SPIO nanoparticles were located within the lysosomes. Conclusions In conclusion, we have demonstrated the feasibility of direct labeling with Ferucarbotran without impairment of cellular function, toxicity, or inhibition of differentiation capacity. Furthermore, lysosomal metabolism takes place after intracellular uptake of Ferucarbotran.
-
The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells.
Toxicology and applied pharmacology, 2010Co-Authors: Ying-chun Chen, Jong-kai Hsiao, Ming Yao, Szu-chun Hsu, Hon-man Liu, I-yin Lai, Yao-chang Chen, Chung-shi Yang, Dong-ming HuangAbstract:Abstract Superparamagnetic iron oxide (SPIO) nanoparticles are very useful for monitoring cell trafficking in vivo and distinguish whether cellular regeneration originated from an exogenous cell source, which is a key issue for developing successful stem cell therapies. However, the impact of SPIO labeling on stem cell behavior remains uncertain. Here, we show the inhibitory effect of Ferucarbotran, an ionic SPIO, on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. Ferucarbotran caused a dose-dependent inhibition of osteogenic differentiation, abolished the differentiation at high concentration, promoted cell migration, and activated the signaling molecules, β-catenin, a cancer/testis antigen, SSX, and matrix metalloproteinase 2 (MMP2). An iron chelator, desferrioxamine, suppressed all the above Ferucarbotran-induced actions, demonstrating an important role of free iron in the inhibition of osteogenic differentiation that is mediated by the promotion of cell mobilization, involving the activation of a specific signaling pathway.
Young Min Han - One of the best experts on this subject based on the ideXlab platform.
-
detection of small hepatocellular carcinoma comparison of conventional gadolinium enhanced mri with gadolinium enhanced mri after the administration of Ferucarbotran
British Journal of Radiology, 2009Co-Authors: Young Kon Kim, C S Kim, Young Min HanAbstract:We compared the diagnostic efficacy of gadolinium (Gd)-enhanced MRI with that of Gd-enhanced MRI after administration of Ferucarbotran for revealing small hypervascular hepatocellular carcinomas (HCCs). 24 patients with 34 HCCs (ranging in size from 0.6–2.0 cm) underwent Gd-enhanced three-dimensional dynamic MRI followed, after an interval of 5–11 days (mean, 7 days), by Gd-enhanced three-dimensional dynamic MRI after administration of Ferucarbotran. The two Gd-enhanced arterial-phase MRI scans were compared quantitatively by measuring the tumour–liver contrast-to-noise ratio (CNR) and qualitatively by evaluating the tumour–liver contrast using matched-pairs analysis. The tumour–liver CNR with Gd-enhanced arterial-phase imaging after Ferucarbotran (250.3 ± 103.7) was higher than that with Gd-enhanced arterial-phase imaging (221.1 ± 96.1) (p < 0.001). Matched-pairs analysis indicated that, for three lesions, the relative tumour–liver contrast was slightly better with Gd-enhanced arterial-phase imaging afte...
-
Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of Ferucarbotran.
The British journal of radiology, 2009Co-Authors: Young Kon Kim, C S Kim, Young Min HanAbstract:We compared the diagnostic efficacy of gadolinium (Gd)-enhanced MRI with that of Gd-enhanced MRI after administration of Ferucarbotran for revealing small hypervascular hepatocellular carcinomas (HCCs). 24 patients with 34 HCCs (ranging in size from 0.6–2.0 cm) underwent Gd-enhanced three-dimensional dynamic MRI followed, after an interval of 5–11 days (mean, 7 days), by Gd-enhanced three-dimensional dynamic MRI after administration of Ferucarbotran. The two Gd-enhanced arterial-phase MRI scans were compared quantitatively by measuring the tumour–liver contrast-to-noise ratio (CNR) and qualitatively by evaluating the tumour–liver contrast using matched-pairs analysis. The tumour–liver CNR with Gd-enhanced arterial-phase imaging after Ferucarbotran (250.3 ± 103.7) was higher than that with Gd-enhanced arterial-phase imaging (221.1 ± 96.1) (p
-
Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus Ferucarbotran-enhanced MR imaging
European journal of radiology, 2008Co-Authors: Young Kon Kim, Young Hwan Lee, Hyo Sung Kwak, Chong Soo Kim, Young Min HanAbstract:Abstract Purpose To compare the diagnostic performance of gadoxetic acid-enhanced MRI with Ferucarbotran-enhanced MRI for the detection of liver metastases. Materials and methods Thirty-six patients with 80 liver metastases who underwent gadoxetic acid-enhanced MRI using a three-dimensional volumetric interpolated technique and Ferucarbotran-enhanced MRI with a mean interval of 7 days (range, 5–10 days) were included in this study. Two observers independently interpreted the two sets of images – the gadoxetic acid set (unenhanced, early dynamic and 20min delayed phase images) and the Ferucarbotran set (unenhanced and Ferucarbotran-enhanced T2*-weighted-gradient echo and T2-weighted turbo spin echo images). Diagnostic accuracy was evaluated using the alternative-free response receiver operator characteristic (ROC) method. Sensitivity and positive predictive value were also evaluated. Results There was a trend toward increased areas under the ROC curve (Az values) for the gadoxetic acid set (0.950, 0.948) as compared with the Ferucarbotran set (0.941 and 0.939) of images, but no significant difference was found for both observers ( p p =0.13). The two image sets showed similar positive predictive values (98.7% and 98.6%, respectively). Conclusions Gadoxetic acid-enhanced MRI showed comparable diagnostic performance to Ferucarbotran-enhanced MRI for the detection of liver metastases.
-
Small Malignant Hepatic Tumor Detection in Gadolinium- and Ferucarbotran-Enhanced Magnetic Resonance Imaging: does Combining Ferucarbotran-Enhanced T2*-Weighted Gradient Echo and T2-Weighted Turbo Spin Echo Images have Additive Efficacy?
Korean journal of radiology, 2008Co-Authors: Young Kon Kim, Young Hwan Lee, Hyo Sung Kwak, Chong Soo Kim, Young Min HanAbstract:OBJECTIVE: To determine if a combination of Ferucarbotran-enhanced T2*weighted-gradient echo (T2*W-GRE) and T2-weighted turbo spin echo (T2W-TSE) images in gadolinium- and Ferucarbotran-enhanced MRI has additive efficacy compared to each image alone for detecting small (< or = 2.0 cm) hepatocellular carcinoma (HCC) lesions in a group of cirrhotic patients and metastases in a group of non-cirrhotic patients. MATERIALS AND METHODS: Two readers retrospectively analyzed gadolinium- and Ferucarbotran-enhanced T2*W-GRE, T2W-TSE, and combined T2*W-GRE/T2W-TSE images of 119 patients with 157 HCCs and 32 patients with 98 metastases. The diagnostic accuracy and sensitivity for each image set and the combined set were evaluated using the alternative-free response receiver operating characteristic method. RESULTS: The mean area under the curve value of the combined set (0.966) tended to be better than that for each individual image set (T2W-TSE [0.910], T2*W-GRE [0.892]). Sensitivities in the combined set were higher than those in each individual image set for detecting HCC (mean, 93.0% versus 81.6% and 86.7%, respectively, p < 0.01). Sensitivities in the combined set and the T2W-TSE set were the same for detecting metastases, and both were higher than the sensitivity seen in the T2*W-GRE set (mean, 97.5% versus 85.2 %, p < 0.01). CONCLUSION: Combining Ferucarbotran-enhanced T2*W-GRE and T2W-TSE has additive efficacy for detecting HCC in cirrhotic patients, but T2W-TSE is preferred for detecting metastases in non-cirrhotic patients.